LMR Partners’s Editas Medicine EDIT Stock Holding History

LMR Partners’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-5,000	Closed	-$283K	–	1049
2021 Q2	$283K	Sell	5,000 -20,000	-80%	-$739K	﹤0.01%	747
2021 Q1	$1.05M	Buy	+25,000	New	+$1.42M	0.03%	465
2017 Q2	–	Sell	-153,190	Closed	-$3.42M	–	622
2017 Q1	$3.42M	Buy	+153,190	New	+$3.17M	0.33%	59

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

LMR Partners's EDIT Position: Q3 2021 in Review

LMR Partners sold out of Editas Medicine (EDIT) in Q3 2021, closing a stake of 5,000 shares — an estimated $283K sold.

LMR Partners first reported a position in EDIT in Q1 2017 and held it in 3 quarters. The position peaked at $3.42M in Q1 2017. 318 funds tracked by Wall St. Rank hold EDIT as of Q3 2021.

LMR Partners reported no remaining Editas Medicine position as of Q3 2021 after selling out during the quarter.
LMR Partners sold 5,000 Editas Medicine shares in Q3 2021, an estimated $283K.
LMR Partners first reported a position in Editas Medicine in Q1 2017 and held it in 3 quarters.
LMR Partners's Editas Medicine position peaked at $3.42M in Q1 2017.
318 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2021.

Based on LMR Partners's 13F filing for Q3 2021, filed 15 Nov 2021.